Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Int Immunopharmacol. 2015 May 21;27(2):224–231. doi: 10.1016/j.intimp.2015.05.018

Fig. 4. GAC1 inhibited TNF-α production by PBMCs from asthma patients.

Fig. 4

Purified PBMCs were treated with or without GAC1 (20 μg/mL) for 24 hours. LPS (2 μg/mL) was added and culture conditions maintained for additional 24 hours. Supernatants were harvested and TNF-α levels were determined by ELISA. (A). GAC1 (20 μg/mL) inhibition of TNF-α production by LPS-stimulated PBMCs from asthma patients. (B). PBMC viability after treatment with GAC1 (20 μg/mL). * p<0.05, paired t-test, (n=11).